ONL Therapeutics, Inc.
ONL Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing first-in-class therapeutics to protect and improve the vision of patients with retinal disease. They focus on protecting key retinal cells from Fas-mediated cell death using innovative technology, aiming to address major unmet medical needs in retinal diseases such as retinal detachment, glaucoma, AMD, and IRD.
Industries
Nr. of Employees
small (1-50)
ONL Therapeutics, Inc.
Ann Arbor, Michigan, United States, North America
Products
Investigational intravitreal Fas-pathway inhibitor (ophthalmic solution)
An investigational intravitreal ophthalmic formulation designed to inhibit Fas-mediated retinal cell death; evaluated in multiple Phase 1/1b and Phase 2 clinical trials for retinal detachment, open-angle glaucoma, and geographic atrophy associated with AMD.
Investigational gene therapy approach for Fas inhibition
A preclinical-to-development gene therapy program intended to achieve Fas pathway inhibition as an alternative modality to small-molecule/peptide inhibitors.
Investigational intravitreal Fas-pathway inhibitor (ophthalmic solution)
An investigational intravitreal ophthalmic formulation designed to inhibit Fas-mediated retinal cell death; evaluated in multiple Phase 1/1b and Phase 2 clinical trials for retinal detachment, open-angle glaucoma, and geographic atrophy associated with AMD.
Investigational gene therapy approach for Fas inhibition
A preclinical-to-development gene therapy program intended to achieve Fas pathway inhibition as an alternative modality to small-molecule/peptide inhibitors.
Services
Clinical development and trial execution
Design and conduct of multicenter ophthalmic clinical trials including safety, pharmacokinetics, dose-ranging and efficacy assessments.
Clinical data management and imaging analysis
Management of trial data and application of imaging analysis workflows, including AI-assisted image analysis for retinal endpoints.
Clinical development and trial execution
Design and conduct of multicenter ophthalmic clinical trials including safety, pharmacokinetics, dose-ranging and efficacy assessments.
Clinical data management and imaging analysis
Management of trial data and application of imaging analysis workflows, including AI-assisted image analysis for retinal endpoints.
Expertise Areas
- Retinal neuroprotection
- Ophthalmic clinical trial management
- Intravitreal formulation development
- CMC and clinical trial material production
Key Technologies
- Fas-pathway inhibition (small-molecule/peptide)
- Intravitreal ophthalmic delivery
- Ophthalmic solution formulation
- Gene therapy vectors for pathway inhibition